News >

Venetoclax Combination Improves PFS in Phase III CLL Trial

Jason M. Broderick @jasoncology
Published: Monday, Sep 18, 2017

Sandra Horning, MD
Sandra Horning, MD
The combination of venetoclax (Venclexta) and rituximab (Rituxan) significantly improved progression-free survival (PFS) compared with rituximab plus bendamustine (Treanda) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to findings from the phase III MURANO study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication
x